Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus

Current Rheumatology Reports

Volumn 9, Issue 2, 2007, Pages 101-108

  Friedman, Deborah M ^b   Rupel, Ann ^b   Buyon, Jill P ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DEXAMETHASONE; IMMUNOGLOBULIN; STEROID;

ADRENAL SUPPRESSION; BRAIN GROWTH; CONGENITAL HEART BLOCK; DIABETES MELLITUS; HUMAN; HYPERTENSION; INCIDENCE; INTRAUTERINE GROWTH RETARDATION; LEARNING DISORDER; LUPUS ERYTHEMATOSUS; MORBIDITY; MORTALITY; NEONATAL LUPUS SYNDROME; OLIGOHYDRAMNIOS; PATHOGENESIS; REVIEW; SIDE EFFECT;

AUTOANTIBODIES; COMORBIDITY; DISEASE TRANSMISSION, VERTICAL; HEART BLOCK; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; LUPUS ERYTHEMATOSUS, SYSTEMIC; SURVIVAL RATE; UNITED STATES;

EID: 34250612325     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0003-4     Document Type: Review

References (48)

1. Buyon JP, Clancy RM: Neonatal lupus. In Dubois' Lupus Erythematosus, 7th edition. Edited by Wallace DJ, Hahn BH. Philadelphia: Lippincott Williams & Wilkins; 2006:1058-1080.
2. Buyon JP, Hiebert, R, Copel J, et al.: Autoimmune-associated congenital heart block: Demographics, mortality, morbidity, and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998, 31:1658-1666.
3. Moak JP, Barron KS, Hougen TJ, et al.: Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001, 37:238-242.
4. Gladman G, Silverman ED, Yuk-Law, et al.: Fetal echocardiographic screening of pregnancies of mothers with anti-Ro and/or anti-La antibodies. Am J Perinatol 2002, 19:73-79.
5. Cimaz R, Spence DL, Hornberger L, Silverman ED: Incidence and spectrum of neonatal lupus erythematosus: A prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003, 142:678-683.
6. Brucato A, Doria A, Frassi M, et al.: Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus 2002, 11:716-721.
7. Askanase AD, Friedman DM, Copel J, et al.: Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002, 11:145-151.
8. Moak JP, Barron KS, Hougen TJ, et al.: Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001, 37:238-242.
9. Nield LE, Silverman ED, Taylor CP, et al.: Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002, 105:843-848.
10. Nield LE, Silverman ED, Smallhorn JF, et al.: Endocardial fibroelastosis associated with maternal anti-Ro and anti-La antibodies in the absence of atrioventricular block. J Am Coll Cardiol 2002, 40:796-802.
11. van der Geld H, Peetoom F, Somers K, Kanyerezi BR: Immunological and serological studies in endomyocardial fibrosis. Lancet 1966, 2:1210-1213.
12. Buyon JP, Waltuck J, Caldwell K, et al.: Relationship between maternal and neonatal levels of antibodies to 48 kDa SSB(La), 52 kDa SSA(Ro), and 60 kDa SSA(Ro) in pregnancies complicated by congenital heart block. J Rheumatol 1994, 21:1943-1950.
13. Salomonsson S, Dörner T, Theander E, et al.: A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 2002, 46:1233-1241.
14. •• Salomonsson S, Sonesson SE, Ottosson L, et al.: Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block. J Exp Med 2005, 201:11-17. A study with clinical and basic components: prospective serial echocardiography of 25 pregnant women with anti-Ro52 antibodies, induction of first-degree atrioventricular block in 20% of pups born to mice immunized with the Ro p200 peptide, demonstration of p200 antibody binding to cell surface, and disruption of calcium homeostasis in neonatal rat cardiomyocytes cultured in vitro.
15. Eftekhari P, Sallé L, Lezoualc'h F, et al.: Anti-SSA/Ro 52 autoantibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block. Eur J Immunol 2000, 30:2782-2790.
16. Eftekhari P, Roegel JC, Lezoualc'h F, et al.: Induction of neonatal lupus in pups of mice immunized with synthetic peptides derived from amino acid sequences of the serotoninergic 5 HT4 receptor. Eur J Immunol 2001, 31:573-578.
17. Buyon JP, Clancy R, Di Donato F, et al.: Cardiac 5-HT4 serotoninergic receptors, 52 K D SSA/Ro and autoimmune-associated congenital heart block. J Autoimmun 2002, 19:79-86.
18. 4 receptor autoantibodies do not have the predictive value of anti-Ro52 autoantibodies, the presence of these antibodies in a minor subset of mothers whose children have CHB suggests an additional risk factor that may contribute to the pathogenesis of disease.
19. Borda E, Sterin-Borda L: Autoantibodies against neonatal heart M1 muscarinic acetylcholine receptor in children with congenital heart block. J Autoimmunity 2001, 16:143-150.
20. Friedman DM, Kim MY, Copel JA, et al.: Utility of cardiac monitoring in fetuses at risk of congenital heart block: The PR interval and dexamethasone evaluation (PRIDE) prospective study [abstract]. Arthritis Rheum 2006, 54(Suppl):S689.
21. •• Clancy RM, Buyon JP, Ikeda K, et al.: Maternal antibody responses to the 52-kd SSA/Ro p200 peptide and the development of fetal conduction defects. Arthritis Rheum 2005, 52:3079-3086. Evaluation of anti-p200 reactivity in sera of 156 subjects and analysis of correlation to clinical history. Interpretation of these data is that reactivity to p200 is a dominant but not uniform anti-Ro52 response in women whose children have CHB. Because exposure to this antibody specificity was observed with a similar frequency in children without CHB born to mothers with anti-Ro52, additional factors are necessary to convert risk to disease expression.
22. Abboud S, Barka G, Mashiach S, Sedeh D: Quantification of the fetal electrocardiogram using averaging technique. Comput Biol Med 1990, 20:147-155.
23. Glickstein JS, Buyon J, Friedman D: Pulsed Doppler echocardiographic assessment of the fetal PR interval. Am J Cardiol 2000, 86:236-239.
24. •• Glickstein J, Buyon J, Kim M, et al.: The fetal Doppler mechanical PR interval: A validation study. Fetal Diagn Ther 2004, 19:31-34. Echocardiograms on 75 healthy fetuses were performed and evaluated by 15 pediatric cardiologists participating in a larger clinical trial involving fetuses at risk for autoantibody-associated CHB. After viewing a teaching tape, each physician measured the pulsed Doppler-derived fetal PR interval on five different subjects. The tapes were sent to a central facility and the same intervals were remeasured by an experienced central reader, who concluded that the pulsed Doppler assessment of the mechanical PR interval in the fetus can be accurately performed after minimal training.
25. Friedman D, Buyon J, Kim M, Glickstein JS: Fetal cardiac function assessed by Doppler myocardial performance index (Tei index). Ultrasound Obstet Gynecol 2003, 21:33-36.
26. Friedman DM, Duncanson LJ, Glickstein J, Buyon JP: A review of congenital heart block. Images Paediatr Cardiol 2003, 16:36-48.
27. Dancea A, Fouron JC, Miro J, et al.: Correlation between electrocardiographic and ultrasoundic time-interval measurements in fetal lamb heart. Pediatr Res 2000, 47:324-328.
28. •• Sonesson SE, Salomonsson S, Jacobsson LA, et al.: Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti-SSA/Ro 52-kd antibodies. Arthritis Rheum 2004, 50:1253-1261. A prospective study using two different methods to measure the mechanical Doppler PR interval serially in 24 anti-Ro/La antibody-positive women between 18 and 24 weeks of gestation, in comparison with 284 control pregnant women.
29. • Rein AJ, Mevorach D, Pedes Z, et al.: Fetal first-degree heart block, or where to set the confidence limit [Comment on Arthritis Rheum 2004, 50:1253-1261.]. Arthritis Rheum 2005, 52:366. The authors agree with Sonesson et al. [28••] that introducing the novel method of utilizing superior vena cava-aorta recordings to measure atrioventricular conduction in the fetus is important, but they suggest a higher limit in defining first-degree heart block.
30. • Buyon JP, Askanase AD, Kim MY, et al.: On identifying an early marker for congenital heart block: when is a long PR interval too long? [Comment on Arthritis Rheum 2004, 50:1253-1261.] Arthritis Rheum 2005, 52:1341-1342. These authors also question the definition of first-degree block, noting that of the eight fetuses with signs of first-degree block described by Sonesson et al. [28••], only three had PR intervals greater than 150 milliseconds, and these included the two fetuses that progressed to having more advanced degrees of block. Of particular interest is the case of first-degree block (atrioventricular interval > 150 milliseconds) that progressed to second-degree block but which, after dexamethasone therapy, reverted to first-degree block at birth and normal sinus rhythm within weeks. This finding supports the notion that a threshold may exist in the cascade to fibrosis, below which reversibility is possible.
31. Hosono T, Shinto M, Chidba Y, et al.: Prenatal diagnosis of fetal complete atrioventricular block with QT prolongation and alternating ventricular pacemakers using multi-channel magnetocardiography and current-arrow maps. Fetal Diagn Ther 2002, 17:173-176.
32. Rein AJ, O'Donnell C, Geva T, et al.: Use of tissue velocity imaging in the diagnosis of fetal cardiac arrhyhmias. Circulation 2002, 106:1827-1833.
33. Saleeb S, Copel J, Friedman D, Buyon JP: Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block. Arthritis Rheum 1999, 42:2335-2345.
34. •• Jaeggi ET, Fouron JC, Silverman ED, et al.: Transplacental fetal treatment improves the outcome of prenatally diagnosed complete atrioventricular block without structural heart disease. Circulation 2004, 110:1542-1548. Analysis of 37 cases of complete atrioventricular block managed between 1990 and 2003. Twenty-two were treated (21 with maternal dexamethasone, eight of whom also received B-adrenergic stimulation, and one with B-adrenergic stimulation only), and 15 were untreated. One-year survival was 90% for the dexamethasone-treated group and 46% for those not receiving dexamethasone (P < 0.02).
35. • Breur JM, Visser GH, Kruize AA, et al.: Treatment of fetal heart block with maternal steroid therapy: case report and review of the literature. Ultrasound Obstet Gynecol 2004, 24:467-472. Case report of one pregnancy in an anti-Ro/La-positive woman receiving dexamethasone, which did not prevent CHB in the fetus and resulted in adverse effects. Also a meta-analysis of 15 previously published reports of 93 cases of fetal CHB treated with maternal steroids.
36. Deloof E, Devlieger H, Van Hoestenberghe R, et al.: Management with a staged approach of the premature hydropic fetus due to complete congenital heart block. Eur J Pediatr 1997, 156:521-523.
37. Groves AM, Allan LD, Rosenthal E: Therapeutic trial of sympathomimetics in three cases of complete heart block in the fetus. Circulation 1995, 92:3394-3396.
38. Robinson BV, Ettedgui JA, Sherman FS: Use of terbutaline in the treatment of complete heart block in the fetus. Cardiol Young 2001, 11:683-686.
39. Carpenter RJ Jr, Strasburger JF, Garson A Jr, et al.: Fetal ventricular pacing for hydrops secondary to complete atrioventricular block. J Am Coll Cardiol 1986, 8:1434-1436.
40. Van der Leij JN, Visser GH, Bink-Boelkens MT, et al.: Successful outcome of pregnancy after treatment of maternal anti-Ro (SSA) antibodies with immunosuppressive therapy and plasmapheresis. Prenat Diagn 1994, 14:1003-1007.
41. Barclay CS, French MA, Ross LD, Sokol RJ: Successful pregnancy following steroid therapy and plasma exchange in a woman with anti-Ro (SS-A) antibodies [case report]. Br J Obstet Gynaecol 1987, 94:369-371.
42. Shinohara K, Miyagawa S, Fujita T, et al.: Neonatal lupus erythematosus: results of maternal corticosteroid therapy. Obstet Gynecol 1999, 93:952-957.
43. Waltuck J, Buyon JP: Autoantibody-associated congenital heart block: Outcome in mothers and children. Ann Intern Med 1994, 120:544-551.
44. Blanford AT, Murphy BE: In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol 1977, 127:264-267.
45. Wong JP, Kwek KY, Tan JY, Yeo GS: Fetal congenital complete heart block: prophylaxis with intravenous gammaglobulin and treatment with dexamethasone. Aust NZ J Obstet Gynaecol 2001, 41:339-341.
46. Tsai YG, Ou TY, Wang CC, et al.: Intravenous gammaglobulin therapy in myocarditis complicated with complete heart block: Report of one case. Acta Paediatr Taiwan 2001, 42:311-313.
47. Kaaja R, Julkunen H: Prevention of recurrence of congenital heart block with intravenous immunoglobulin and corticosteroid therapy: comment on the editorial by Buyon et al. Arthritis Rheum 2003, 48:280-281.
48. Branch DW, Porter TF, Paidas MJ, et al.: Obstetric uses of intravenous immunoglobulin: successes, failures and promises. J Allergy Clin Immunol 2001, 108:S133-138.